New immunotherapy MK-1045 enters first human trial for Hard-to-Treat lymphoma
NCT ID NCT06189391
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug called MK-1045 (CN201) in about 100 people whose B-cell non-Hodgkin lymphoma has returned or stopped responding to treatment. MK-1045 is an immunotherapy designed to help the immune system fight the cancer. The main goals are to check the drug's safety, find the best dose, and see if it shows any signs of working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MK-1045 (also called CN201), an immunotherapy drug given by IV infusion
- What this could lead to
- If it works, this could point toward a new treatment option for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to other therapies.
- What could go wrong
- This is a very early (Phase 1) trial with only 100 participants, so it is not yet known if MK-1045 is safe or effective. Side effects could be serious, and the drug may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Beijing Cancer hospital ( Site 0001)
RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Fifth Medical Center of PLA General Hospital ( Site 0005)
RECRUITINGBeijing, Beijing Municipality, 100071, China
-
Fudan University Shanghai Cancer Center ( Site 0012)
RECRUITINGShanghai, Shanghai Municipality, 200030, China
-
Henan Cancer Hospital ( Site 0009)
RECRUITINGZhengzhou, Henan, 450000, China
-
Jiangxi Cancer Hospital ( Site 0007)
RECRUITINGNanchang, Jiangxi, 330029, China
-
Shandong Cancer Hospital ( Site 0008)
ACTIVE_NOT_RECRUITINGJinan, Shandong, 250117, China
-
Shanghai East Hospital ( Site 0002)
RECRUITINGShanghai, Shanghai Municipality, 200120, China
-
Sichuan Cancer Hospital. ( Site 0018)
RECRUITINGChengdu, Sichuan, 610041, China
-
Sun Yat-Sen University Cancer Center ( Site 0003)
RECRUITINGGuangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Xiamen University ( Site 0011)
RECRUITINGXiameng, Fujian, 361000, China
-
The First Affiliated Hospital of Zhengzhou University ( Site 0006)
RECRUITINGZhengzhou, Henan, 451161, China
-
The First Hospital Of Jilin University ( Site 0014)
RECRUITINGChangchun, Jilin, 130021, China
-
The Fourth Hospital of Hebei Medical University. ( Site 0004)
RECRUITINGShijiazhuang, Hebei, 050035, China
-
Tianjin Medical University Cancer Institute and Hospital ( Site 0010)
ACTIVE_NOT_RECRUITINGTianjinc, Tianjin Municipality, 300060, China
-
Zhongshan Hospital,Fudan University ( Site 0013)
RECRUITINGShanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a targeted pill boost Chemotherapy's punch against lymphoma?